DIABIO Stock Overview
Operates as a biotechnology company in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Diagonal Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.014 |
| 52 Week High | SEK 0.097 |
| 52 Week Low | SEK 0.0063 |
| Beta | -1.83 |
| 1 Month Change | 7.69% |
| 3 Month Change | -16.17% |
| 1 Year Change | -76.11% |
| 3 Year Change | -99.53% |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| DIABIO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 7.7% | -0.6% | 0.2% |
| 1Y | -76.1% | -1.8% | -4.3% |
Return vs Industry: DIABIO underperformed the Swedish Biotechs industry which returned -0.8% over the past year.
Return vs Market: DIABIO underperformed the Swedish Market which returned -4.5% over the past year.
Price Volatility
| DIABIO volatility | |
|---|---|
| DIABIO Average Weekly Movement | 17.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 14.3% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: DIABIO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: DIABIO's weekly volatility has decreased from 31% to 18% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 5 | Karin Wehlin | diagonalbio.com |
Diagonal Bio AB (publ) operates as a biotechnology company in Sweden. The company offers LAMPlify, a customized system for general laboratory use to identify the presence of specific genetic markers for, for example, fungi, viruses, or bacteria. It is also involved in the development of PANVIRAL, a universal in vitro diagnostic system, that offers the potential for rapid and accurate point-of-care diagnoses in various settings, such as doctor’s office, surgery, mobile clinics, hospital bedsides, and workplaces and airports.
Diagonal Bio AB (publ) Fundamentals Summary
| DIABIO fundamental statistics | |
|---|---|
| Market cap | SEK 15.79m |
| Earnings (TTM) | -SEK 9.93m |
| Revenue (TTM) | SEK 1.13m |
15.1x
P/S Ratio-1.7x
P/E RatioIs DIABIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIABIO income statement (TTM) | |
|---|---|
| Revenue | SEK 1.13m |
| Cost of Revenue | SEK 183.00k |
| Gross Profit | SEK 942.00k |
| Other Expenses | SEK 10.87m |
| Earnings | -SEK 9.93m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 14, 2025
| Earnings per share (EPS) | -0.0082 |
| Gross Margin | 83.73% |
| Net Profit Margin | -882.67% |
| Debt/Equity Ratio | 0% |
How did DIABIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 10:09 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diagonal Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.